Archive | News

PDA Europe 2017

Oval Medical Technologies and SMC Ltd. will be attending PDA Europe in Vienna from the 6th-8th November 2017. We will be exhibiting at booth 100 and 101 and would welcome the opportunity to discuss and demonstrate our delivery platforms and integrated approach to autoinjector design. We will also be demonstrating our injection characterisation system which […]

Continue Reading

SMC Ltd. Expands Drug Delivery Capabilities with Oval Medical Technologies Acquisition

Somerset, Wisconsin – SMC Ltd., a global contract manufacturer of pharmaceutical and finished medical devices, announced today that it has acquired Oval Medical Technologies Ltd., a specialty pharmaceutical device company developing next generation autoinjectors based in Cambridge, UK.   Oval’s autoinjector platforms address the unmet needs in the self-injection market utilizing both cyclic olefin plastic […]

Continue Reading

Oval Medical CEO to participate in Industry Roundtable at Annual Meeting of the Controlled Release Society

Oval Medical’s CEO, Ms Barbara Lead will be one of the panellists in the Industry Roundtable “Drugs, Delivery, and Patients – How Will We Bring It All Together in the New World?” at the Annual Meeting of the Controlled Release Society on Sunday July 26th. The panel discussion, moderated by Ms Debra Bingham (Partner at […]

Continue Reading

Oval Medical appoints new CEO

The board of Oval Medical Technologies Limited (‘Oval’) announces that effective from 1st May 2013, Barbara Lead has succeeded Dr Catherine Beech as Chief Executive Officer of Oval Medical Technologies Limited. Catherine was instrumental in establishing Oval with Matthew Young in late 2009 and completing the initial Angel financing in early 2010. Since then, with […]

Continue Reading

Oval Medical announces the availability of functional prototypes

30th May 2013 – Oval Medical Technologies Ltd (‘Oval’), today have announced that functional prototypes of their autoinjector technology are now available. Oval’s specification for a standard 1ml device was clearly met by delivering 1ml of drug subcutaneously, through a 27G needle in less than 7 seconds. The fully functional injection-moulded prototypes demonstrate the simplicity […]

Continue Reading

Revolutionary autoinjector pushes the limits of high viscosity drug delivery

17th April 2013 – Oval Medical Technologies Ltd (‘Oval’), today have announced that a variety of 1100 cPs solutions (the thickness of motor oil) have been successfully delivered through a 25G thin wall needle, in less than 7 seconds, using their revolutionary autoinjector. Oval is a cutting-edge autoinjector company based in Cambridge UK. Their autoinjector […]

Continue Reading

Oval Medical receives ISO 13485:2012 certification for medical device development

21st February 2013 – Oval Medical Technologies Ltd (‘Oval’), the privately held autoinjector development company, today announced that is has been awarded BS EN ISO 13485:2012 certification. ISO 13485 is a quality standard certifying that the company has a comprehensive management system in place for the design, development and manufacture of drug delivery devices. This […]

Continue Reading

Oval Medical Technologies signs key agreement with leading global pharmaceutical company

May 14th, 2012 – Oval Medical Technologies Ltd. (“Oval”), the company developing the next generation of autoinjectors, today announced that they have entered into an agreement with a top ten global pharmaceutical company to evaluate one of their leading prescription drugs in Oval’s novel autoinjector technology. Under the terms of Agreement, the pharmaceutical company has […]

Continue Reading

Oval Medical collaborates with the Cambridge University MBA Venture Project

6th February 2012 – Cambridge-based Oval Medical Technologies Limited (“Oval Medical”) has recently collaborated on the Cambridge Venture Project (CVP), part of the MBA programme at the Judge Business School, University of Cambridge. Oval Medical has developed a unique autoinjector and syringe technology that will allow patients of different ages and from various therapeutic areas […]

Continue Reading